Inavolisib-Based Therapy in <i>PIK3CA</i> -Mutated Advanced Breast CancerNicholas C. Turner, Komal Jhaveri, Huiping Li et al.|New England Journal of Medicine|2024Cited by 235
A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patientsHuiping Li, Erwei Song|Nature Communications|2018Cited by 106
Pyrotinib versus placebo in combination with trastuzumab and docetaxel as first line treatment in patients with HER2 positive metastatic breast cancer (PHILA): randomised, double blind, multicentre, phase 3 trialFei Ma, Binghe Xu, Min Yan et al.|BMJ|2023Cited by 82
Peripheral CD8+CD28- T cell level reflects tumor immunity and could predict anti- HER2 based therapy response in metastatic breast cancerHuiping Li, Yiqiang Liu|Research Square|2022Cited by 0
Persistence of peripheral CD8 + CD28− T cells indicates a favourable outcome and tumour immunity in first-line HER2-positive metastatic breast cancerXiaoran Liu, Huiping Li|British Journal of Cancer|2024Cited by 0